Litcius/Paper detail

Production, titration, neutralisation and storage of SARS-CoV-2 lentiviral pseudotypes

Cecilia Di Genova, Alex Sampson, Simon Scott, Diego Cantoni, Martin Mayora Neto, Emma Bentley, Giada Mattiuzzo, Edward Wright, Mariliza Derveni, Bethany Auld, Bill T. Ferrara, D. A. Harrison, Mohamed A. Said, Arwa Selim, Elinor Thompson, Craig Thompson, George Carnell, Nigel Temperton

2020Figshare17 citationsDOIOpen Access PDF

Abstract

This protocol details a rapid and reliable method for the production and titration of high-titer viral pseudotype particles with the SARS-CoV-2 spike protein (and D614G variant) on a lentiviral vector core, and use for neutralization assays in target cells expressing ACE2 and TMPRSS2. It additionally provides detailed instruction on substituting in new spike variants via gene cloning, and storage/shipping considerations for wide deployment potential. Results obtained with this protocol show that SARS-CoV-2 pseudotypes can be produced at equivalent titers to SARS-CoV and MERS-CoV pseudotypes, that they can be neutralized by human convalescent plasma and monoclonal antibodies and that they can be stored at a range of laboratory temperatures and lyophilized for distribution.<br>

Topics & Concepts

NeutralizationVirologyTiterMonoclonal antibodyTitrationNeutralizing antibodyViral vectorSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)ChemistryAntibodyBiologyMolecular biologyVirusGeneImmunologyMedicineBiochemistryRecombinant DNAInfectious disease (medical specialty)Inorganic chemistryDiseasePathologySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingVirus-based gene therapy research
Production, titration, neutralisation and storage of SARS-CoV-2 lentiviral pseudotypes | Litcius